Browsing Other ICR Research by author "Buus, Richard"
Now showing items 1-2 of 2
-
Class II phosphoinositide 3-kinase C2β regulates a novel signaling pathway involved in breast cancer progression.
Chikh, A; Ferro, R; Abbott, JJ; Piñeiro, R; Buus, R; et al. (IMPACT JOURNALS LLC, 2016-04-05)It is now well established that the enzymes phosphoinositide 3-kinases (PI3Ks) have a key role in the development and progression of many cancer types and indeed PI3Ks inhibitors are currently being tested in clinical ... -
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.
Sestak, I; Martín, M; Dubsky, P; Kronenwett, R; Rojo, F; et al. (SPRINGER, 2019-07-01)PURPOSE: EndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemotherapy to endocrine therapy alone for patients with oestrogen receptor-positive, HER2-negative breast cancer. Here, we ...